2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them
Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2-membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
1. A method of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the treatment of damages caused by reperfusion after ischemia comprising administering a compound of formula (Ia):
or a pharmaceutically acceptable salt thereof,
wherein
A is selected from benzene, naphthalene, pyridine, pyrimidine, pyrrole, imidazole, furane, thiophene, indole and 7-aza-indole and labels 1 and 2 mark the relevant positions on the A ring;
the X atom is selected from N (nitrogen) and C (carbon);
R is a substituting group on the A ring selected from:
a group in the 3 position selected from a linear or branched C 1 -C 5 alkyl, C 2 -C 5 -alkenyl or C 2 -C 5 -alkynyl group, substituted or not-substituted phenyl, linear or branched C 1 -C 5 hydroxyalkyl, C 2 -C 5 -acyl, substituted or not-substituted benzoyl;
a group in the 4 position selected from C 1 -C 5 alkyl, C 2 -C 5 -alkenyl or C 2 -C 5 -alkynyl group, C 3 -C 6 -cycloalkyl, C 1 -C 5 -acyloxy, substituted or not-substituted benzoyloxy, C 1 -C 5 -acylamino, substituted or not-substituted benzoylamino, C 1 -C 5 -sulfonyloxy, substituted or not-substituted benzenesulfonyloxy, C 1 -C 5 -alkanesulfonylamino, substituted or not-substituted benzenesulfonylamino, C 1 -C 5 -alkanesulfonylmethyl, substituted or not-substituted benzenesulfonylmethyl, 2-furyl; 3-tetrahydrofuryl; 2 thiophenyl; 2-tetrahydrothiophenyl groups or a C 1 -C 8 -alkanoyl, cycloalkanoyl or arylalkanoyl-C 1 -C 5 -alkylamino group;
Hy is selected from the group consisting of methyl, ethyl, chlorine, bromine, methoxy and trifluoromethyl
Rd is C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, or C 2 -C 6 -alkenyl.
2. The method according to claim 1 , wherein Rd is methyl, ethyl or isopropyl.
3. The method according to any of claim 1 or 2 , wherein R is 3′-benzoyl, 3′-(4-chloro-benzoyl), 3′-(4-methyl-benzoyl), 3′-acetyl, 3′-propionyl, 3′-isobutanoyl, 3′-ethyl, 3′-isopropyl, 4′-isobutyl, 4′-trifluoromethanesulphonyloxy, 4′-benzenesulphonyloxy, 4′-trifluoromethanesulphonylamino, 4′-benzenesulphonylamino, 4′-benzenesulphonylmethyl, 4′-acetyloxy, 4′-propionyloxy, 4′-benzoyloxy, 4′acetylamino, 4′propionylamino, 4′-benzoylamino.
4. The method according to claim 1 , wherein the compound is selected from:
(5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide,
(4-isobutyl-2-methylphenyl)acetyl methanesulphonamide,
{2-methyl-4-[(trifluoromethanesulphonyl)amino]phenyl}acetyl methanesulphonamide, and
[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl methanesulphonamide.
5. A compound of formula (Ia)
or a pharmaceutically acceptable salt thereof,
wherein:
A is selected from benzene, naphthalene, pyridine, pyrimidine, pyrrole, imidazole, furane, thiophene, indole and 7-aza-indole and labels 1 and 2 mark the relevant positions on the A ring;
the X atom is selected from N (nitrogen) and C (carbon);
R is a substituting group on the A ring selected from:
a group in the 3 position selected from a linear or branched C 1 -C 5 alkyl, C 2 -C 5 -alkenyl or C 2 -C 5 -alkynyl group, substituted or not-substituted phenyl, linear or branched C 1 -C 5 hydroxyalkyl, C 2 -C 5 -acyl, substituted or not-substituted benzoyl;
a group in the 4 position selected from C 1 -C 5 alkyl, C 2 -C 5 -alkenyl or C 2 -C 5 -alkynyl group, C 3 -C 6 -cycloalkyl, C 1 -C 5 -acyloxy, substituted or not-substituted benzoyloxy, C 1 -C 5 -acylamino, substituted or not-substituted benzoylamino, C 1 -C 5 -sulfonyloxy, substituted or not-substituted benzenesulfonyloxy, C 1 -C 5 -alkanesulfonylamino, substituted or not-substituted benzenesulfonylamino, C 1 -C 5 -alkanesulfonylmethyl, substituted or not-substituted benzenesulfonylmethyl, 2-furyl; 3-tetrahydrofuryl; 2-thiophenyl; 2-tetrahydrothiophenyl groups or a C 1 -C 8 -alkanoyl, cycloalkanoyl or arylalkanoyl-C 1 -C 5 -alkylamino group;
Hy is selected from methyl, ethyl, chlorine, bromine, methoxy and trifluoromethyl
Rd is C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 2 -C 6 -alkenyl.
6. The compound according to claim 5 , wherein
A is selected from benzene, pyridine, pyrimidine, pyrrole, imidazole, furane, thiophene and indole;
Rd is selected from methyl, ethyl and isopropyl;
Hy is selected from methyl, ethyl, chlorine, bromine, methoxy and trifluoromethyl.
7. A compound selected from
(5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide,
(4-isobutyl-2-methylphenyl)acetyl methanesulphonamide,
{2-methyl-4-[(trifluoromethanesulphonyl)amino]phenyl}acetyl methanesulphonamide, and
[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl methanesulphonamide.
8. A process for the preparation of compounds of formula (Ia),
comprising transforming a compound of formula (I),
wherein
A is benzene, naphthalene, pyridine, pyrimidine, pyrrole, imidazole, furane, thiophene, indole or 7-aza-indole;
labels 1 and 2 mark the relevant positions on the A ring;
the X atom is selected from N (nitrogen) and C (carbon);
R is a substituting group on the A ring selected from:
a group in the 3 position selected from a linear or branched C 1 -C 5 alkyl, C 2 -C 5 -alkenyl or C 2 -C 5 -alkynyl group, substituted or not-substituted phenyl, linear or branched C 1 -C 5 hydroxyalkyl, C 2 -C 5 -acyl, substituted or not-substituted benzoyl;
a group in the 4 position selected from C 1 -C 5 alkyl, C 2 -C 5 -alkenyl or C 2 -C 5 -alkynyl group, C 3 -C 6 -cycloalkyl, C 1 -C 5 -acyloxy, substituted or not-substituted benzoyloxy, C 1 -C 5 -acylamino, substituted or not-substituted benzoylamino, C 1 -C 5 -sulfonyloxy, substituted or not-substituted benzenesulfonyloxy, C 1 -C 5 -alkanesulfonylamino, substituted or not-substituted benzenesulfonylamino, C 1 -C 5 -alkanesulfonylmethyl, substituted or not-substituted benzenesulfonylmethyl, 2-furyl; 3-tetrahydrofuryl; 2 thiophenyl; 2-tetrahydrothiophenyl groups or a C 1 -C 8 -alkanoyl, cycloalkanoyl or arylalkanoyl-C 1 -C 5 -alkylamino group;
Hy is selected from the group consisting of methyl, ethyl, chlorine, bromine, methoxy and trifluoromethyl; and
YR′ is OH; to a reactive intermediate, and reacting the intermediate with a compound of formula NH 2 SO 2 Rd, wherein Rd is C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, or C 2 -C 6 -alkenyl, in the presence of a suitable base.
9. Pharmaceutical compositions comprising a compound according to claim 5 in admixture with a suitable carrier thereof.
10. The process of claim 8 wherein said reactive intermediate is an acyl chloride or a benzotriazolyl ester.